Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is a biopharmaceutical company with promising product candidates targeting C5a and its receptor C5aR to treat various autoimmune and inflammatory diseases. Management is actively discussing options for advancing their lead asset izicopan towards ANCA-associated vasculitis, which could have a significant impact on the company's market potential. The company has also highlighted potential opportunities for izicopan in other renal diseases, such as IgA Nephropathy, and has spoken of a possible renal basket trial. With a robust pipeline and potential for partnerships and collaborations, InflaRx has a strong outlook in the biopharmaceutical industry.

Bears say

InflaRx is facing risks in their clinical development plans for izicopan, an anti-C5a monoclonal antibody, in the treatment of AAV due to potential difficulties in study design and enrollment criteria. Additionally, their potential dosing strategy of 60 mg BID may not be optimal, and they likely won't conduct a head-to-head study against AMGN's Tavneos, suggesting potential for inferior efficacy compared to the currently-marketed drug. Furthermore, there are concerns about Tavneos' safety profile and potential withdrawal from the market, leading to conservative valuation estimates and a negative outlook on InflaRx's stock.

InflaRx (IFRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 6 analysts, InflaRx (IFRX) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.